Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
Identifieur interne : 000F79 ( Main/Exploration ); précédent : 000F78; suivant : 000F80Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
Auteurs : Alison Krentel [Royaume-Uni] ; Rita Damayanti [Indonésie] ; Christiana Rialine Titaley [Indonésie] ; Nugroho Suharno [Indonésie] ; Mark Bradley [Royaume-Uni] ; Timothy Lynam [Australie]Source :
- PLoS neglected tropical diseases [ 1935-2735 ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (usage thérapeutique), Animaux, Calendrier d'administration des médicaments, Caractéristiques familiales, Enquêtes et questionnaires, Femelle, Filaricides (administration et posologie), Filaricides (ressources et distribution), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (parasitologie), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Indonésie (épidémiologie), Jeune adulte, Maladies endémiques (), Mâle, Observance du traitement médicamenteux, Santé mondiale, Services de médecine préventive (normes), Services de médecine préventive (organisation et administration), Wuchereria bancrofti (), Éradication de maladie (), Éradication de maladie (normes).
- MESH :
- administration et posologie : Filaricides.
- normes : Services de médecine préventive, Éradication de maladie.
- organisation et administration : Services de médecine préventive.
- parasitologie : Filariose lymphatique.
- ressources et distribution : Filaricides.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Filaricides.
- épidémiologie : Filariose lymphatique, Indonésie.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Calendrier d'administration des médicaments, Caractéristiques familiales, Enquêtes et questionnaires, Femelle, Filariose lymphatique, Humains, Jeune adulte, Maladies endémiques, Mâle, Observance du traitement médicamenteux, Santé mondiale, Wuchereria bancrofti, Éradication de maladie.
English descriptors
- KwdEn :
- Adolescent, Adult, Albendazole (therapeutic use), Animals, Disease Eradication (methods), Disease Eradication (standards), Drug Administration Schedule, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (parasitology), Elephantiasis, Filarial (prevention & control), Endemic Diseases (prevention & control), Family Characteristics, Female, Filaricides (administration & dosage), Filaricides (supply & distribution), Filaricides (therapeutic use), Global Health, Humans, Indonesia (epidemiology), Male, Medication Adherence, Middle Aged, Preventive Health Services (organization & administration), Preventive Health Services (standards), Surveys and Questionnaires, Wuchereria bancrofti (drug effects), Young Adult.
- MESH :
- chemical , administration & dosage : Filaricides.
- chemical , supply & distribution : Filaricides.
- chemical , therapeutic use : Albendazole, Filaricides.
- drug effects : Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial, Indonesia.
- methods : Disease Eradication.
- organization & administration : Preventive Health Services.
- parasitology : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial, Endemic Diseases.
- standards : Disease Eradication, Preventive Health Services.
- Adolescent, Adult, Animals, Drug Administration Schedule, Family Characteristics, Female, Global Health, Humans, Male, Medication Adherence, Middle Aged, Surveys and Questionnaires, Young Adult.
Abstract
As the Global Programme to Eliminate Lymphatic Filariasis (LF) approaches its 2020 goal, an increasing number of districts will enter the endgame phase where drug coverage rates from mass drug administration (MDA) are used to assess whether MDA can be stopped. As reported, the gap between reported and actual drug coverage in some contexts has overestimated the true rates, thus causing premature administration of transmission assessment surveys (TAS) that detect ongoing LF transmission. In these cases, districts must continue with additional rounds of MDA. Two districts in Indonesia (Agam District, Depok City) fit this criteria-one had not met the pre-TAS criteria and the other, had not passed the TAS criteria. In both cases, the district health teams needed insight into their drug delivery programs in order to improve drug coverage in the subsequent MDA rounds.
DOI: 10.1371/journal.pntd.0005027
PubMed: 27812107
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000531
- to stream PubMed, to step Curation: 000531
- to stream PubMed, to step Checkpoint: 000531
- to stream Ncbi, to step Merge: 008974
- to stream Ncbi, to step Curation: 008974
- to stream Ncbi, to step Checkpoint: 008974
- to stream Main, to step Merge: 000F81
- to stream Main, to step Curation: 000F79
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.</title><author><name sortKey="Krentel, Alison" sort="Krentel, Alison" uniqKey="Krentel A" first="Alison" last="Krentel">Alison Krentel</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Damayanti, Rita" sort="Damayanti, Rita" uniqKey="Damayanti R" first="Rita" last="Damayanti">Rita Damayanti</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia.</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Titaley, Christiana Rialine" sort="Titaley, Christiana Rialine" uniqKey="Titaley C" first="Christiana Rialine" last="Titaley">Christiana Rialine Titaley</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia.</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Suharno, Nugroho" sort="Suharno, Nugroho" uniqKey="Suharno N" first="Nugroho" last="Suharno">Nugroho Suharno</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia.</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Bradley, Mark" sort="Bradley, Mark" uniqKey="Bradley M" first="Mark" last="Bradley">Mark Bradley</name><affiliation wicri:level="3"><nlm:affiliation>Global Health Programs, GlaxoSmithKline, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Health Programs, GlaxoSmithKline, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lynam, Timothy" sort="Lynam, Timothy" uniqKey="Lynam T" first="Timothy" last="Lynam">Timothy Lynam</name><affiliation wicri:level="1"><nlm:affiliation>Reflecting Society Pty Ltd, Townsville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Reflecting Society Pty Ltd, Townsville</wicri:regionArea><wicri:noRegion>Townsville</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27812107</idno><idno type="pmid">27812107</idno><idno type="doi">10.1371/journal.pntd.0005027</idno><idno type="wicri:Area/PubMed/Corpus">000531</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000531</idno><idno type="wicri:Area/PubMed/Curation">000531</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000531</idno><idno type="wicri:Area/PubMed/Checkpoint">000531</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000531</idno><idno type="wicri:Area/Ncbi/Merge">008974</idno><idno type="wicri:Area/Ncbi/Curation">008974</idno><idno type="wicri:Area/Ncbi/Checkpoint">008974</idno><idno type="wicri:Area/Main/Merge">000F81</idno><idno type="wicri:Area/Main/Curation">000F79</idno><idno type="wicri:Area/Main/Exploration">000F79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.</title><author><name sortKey="Krentel, Alison" sort="Krentel, Alison" uniqKey="Krentel A" first="Alison" last="Krentel">Alison Krentel</name><affiliation wicri:level="3"><nlm:affiliation>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Damayanti, Rita" sort="Damayanti, Rita" uniqKey="Damayanti R" first="Rita" last="Damayanti">Rita Damayanti</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia.</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Titaley, Christiana Rialine" sort="Titaley, Christiana Rialine" uniqKey="Titaley C" first="Christiana Rialine" last="Titaley">Christiana Rialine Titaley</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia.</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Suharno, Nugroho" sort="Suharno, Nugroho" uniqKey="Suharno N" first="Nugroho" last="Suharno">Nugroho Suharno</name><affiliation wicri:level="1"><nlm:affiliation>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia.</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Center for Health Research, Faculty of Public Health, Universitas Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Bradley, Mark" sort="Bradley, Mark" uniqKey="Bradley M" first="Mark" last="Bradley">Mark Bradley</name><affiliation wicri:level="3"><nlm:affiliation>Global Health Programs, GlaxoSmithKline, London, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Global Health Programs, GlaxoSmithKline, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lynam, Timothy" sort="Lynam, Timothy" uniqKey="Lynam T" first="Timothy" last="Lynam">Timothy Lynam</name><affiliation wicri:level="1"><nlm:affiliation>Reflecting Society Pty Ltd, Townsville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Reflecting Society Pty Ltd, Townsville</wicri:regionArea><wicri:noRegion>Townsville</wicri:noRegion></affiliation></author></analytic><series><title level="j">PLoS neglected tropical diseases</title><idno type="eISSN">1935-2735</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Disease Eradication (methods)</term><term>Disease Eradication (standards)</term><term>Drug Administration Schedule</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Endemic Diseases (prevention & control)</term><term>Family Characteristics</term><term>Female</term><term>Filaricides (administration & dosage)</term><term>Filaricides (supply & distribution)</term><term>Filaricides (therapeutic use)</term><term>Global Health</term><term>Humans</term><term>Indonesia (epidemiology)</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Preventive Health Services (organization & administration)</term><term>Preventive Health Services (standards)</term><term>Surveys and Questionnaires</term><term>Wuchereria bancrofti (drug effects)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Calendrier d'administration des médicaments</term><term>Caractéristiques familiales</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Filaricides (administration et posologie)</term><term>Filaricides (ressources et distribution)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Filariose lymphatique (parasitologie)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (épidémiologie)</term><term>Humains</term><term>Indonésie (épidémiologie)</term><term>Jeune adulte</term><term>Maladies endémiques ()</term><term>Mâle</term><term>Observance du traitement médicamenteux</term><term>Santé mondiale</term><term>Services de médecine préventive (normes)</term><term>Services de médecine préventive (organisation et administration)</term><term>Wuchereria bancrofti ()</term><term>Éradication de maladie ()</term><term>Éradication de maladie (normes)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Indonesia</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Disease Eradication</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Services de médecine préventive</term><term>Éradication de maladie</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Services de médecine préventive</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Preventive Health Services</term></keywords><keywords scheme="MESH" qualifier="parasitologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Endemic Diseases</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Disease Eradication</term><term>Preventive Health Services</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term><term>Indonésie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Drug Administration Schedule</term><term>Family Characteristics</term><term>Female</term><term>Global Health</term><term>Humans</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Calendrier d'administration des médicaments</term><term>Caractéristiques familiales</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Filariose lymphatique</term><term>Humains</term><term>Jeune adulte</term><term>Maladies endémiques</term><term>Mâle</term><term>Observance du traitement médicamenteux</term><term>Santé mondiale</term><term>Wuchereria bancrofti</term><term>Éradication de maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As the Global Programme to Eliminate Lymphatic Filariasis (LF) approaches its 2020 goal, an increasing number of districts will enter the endgame phase where drug coverage rates from mass drug administration (MDA) are used to assess whether MDA can be stopped. As reported, the gap between reported and actual drug coverage in some contexts has overestimated the true rates, thus causing premature administration of transmission assessment surveys (TAS) that detect ongoing LF transmission. In these cases, districts must continue with additional rounds of MDA. Two districts in Indonesia (Agam District, Depok City) fit this criteria-one had not met the pre-TAS criteria and the other, had not passed the TAS criteria. In both cases, the district health teams needed insight into their drug delivery programs in order to improve drug coverage in the subsequent MDA rounds.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Indonésie</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Krentel, Alison" sort="Krentel, Alison" uniqKey="Krentel A" first="Alison" last="Krentel">Alison Krentel</name></region><name sortKey="Bradley, Mark" sort="Bradley, Mark" uniqKey="Bradley M" first="Mark" last="Bradley">Mark Bradley</name></country><country name="Indonésie"><noRegion><name sortKey="Damayanti, Rita" sort="Damayanti, Rita" uniqKey="Damayanti R" first="Rita" last="Damayanti">Rita Damayanti</name></noRegion><name sortKey="Suharno, Nugroho" sort="Suharno, Nugroho" uniqKey="Suharno N" first="Nugroho" last="Suharno">Nugroho Suharno</name><name sortKey="Titaley, Christiana Rialine" sort="Titaley, Christiana Rialine" uniqKey="Titaley C" first="Christiana Rialine" last="Titaley">Christiana Rialine Titaley</name></country><country name="Australie"><noRegion><name sortKey="Lynam, Timothy" sort="Lynam, Timothy" uniqKey="Lynam T" first="Timothy" last="Lynam">Timothy Lynam</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27812107
|texte= Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27812107" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |